These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32161442)

  • 1. Combination Treatment of Cervical Cancer Using Folate-Decorated, pH-Sensitive, Carboplatin and Paclitaxel Co-Loaded Lipid-Polymer Hybrid Nanoparticles.
    Wang J
    Drug Des Devel Ther; 2020; 14():823-832. PubMed ID: 32161442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles.
    Liu J; Cheng H; Han L; Qiang Z; Zhang X; Gao W; Zhao K; Song Y
    Drug Des Devel Ther; 2018; 12():3199-3209. PubMed ID: 30288024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
    Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
    Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoma-targeted treatment using a folic acid-decorated vincristine-loaded drug delivery system.
    Qiu L; Dong C; Kan X
    Drug Des Devel Ther; 2018; 12():863-872. PubMed ID: 29713144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
    Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
    Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
    Li C; Ge X; Wang L
    Biomed Pharmacother; 2017 Feb; 86():628-636. PubMed ID: 28027539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel/IR1061-Co-Loaded Protein Nanoparticle for Tumor-Targeted and pH/NIR-II-Triggered Synergistic Photothermal-Chemotherapy.
    He L; Qing F; Li M; Lan D
    Int J Nanomedicine; 2020; 15():2337-2349. PubMed ID: 32308385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.
    Zhang W; Li C; Shen C; Liu Y; Zhao X; Liu Y; Zou D; Gao Z; Yue C
    Drug Deliv; 2016 Sep; 23(7):2575-2580. PubMed ID: 26056720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.
    Qian J; Xu N; Zhou X; Shi K; Du Q; Yin X; Zhao Z
    Int J Nanomedicine; 2019; 14():7431-7446. PubMed ID: 31686815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor drug delivery system based on cyclodextrin-containing pH-responsive star polymer: in vitro and in vivo evaluation.
    Xiong Q; Zhang M; Zhang Z; Shen W; Liu L; Zhang Q
    Int J Pharm; 2014 Oct; 474(1-2):232-40. PubMed ID: 25149124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
    Li B; Tan T; Chu W; Zhang Y; Ye Y; Wang S; Qin Y; Tang J; Cao X
    Drug Deliv; 2022 Dec; 29(1):75-88. PubMed ID: 34964421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity.
    Jian Y; Zhao M; Cao J; Fan T; Bu W; Yang Y; Li W; Zhang W; Qiao Y; Wang J; Wen A
    Drug Des Devel Ther; 2020; 14():2355-2370. PubMed ID: 32606603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate-receptor-targeted laser-activable poly(lactide-
    Liu F; Chen Y; Li Y; Guo Y; Cao Y; Li P; Wang Z; Gong Y; Ran H
    Int J Nanomedicine; 2018; 13():5139-5158. PubMed ID: 30233177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
    Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
    Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione-sensitive and folate-targeted nanoparticles loaded with paclitaxel to enhance oral squamous cell carcinoma therapy.
    Fan L; Wang J; Xia C; Zhang Q; Pu Y; Chen L; Chen J; Wang Y
    J Mater Chem B; 2020 Apr; 8(15):3113-3122. PubMed ID: 32207763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic Acid Capped, Irinotecan and Gene Co-Loaded Lipid-Polymer Hybrid Nanocarrier-Based Combination Therapy Platform for Colorectal Cancer.
    Wang Z; Zang A; Wei Y; An L; Hong D; Shi Y; Zhang J; Su S; Fang G
    Drug Des Devel Ther; 2020; 14():1095-1105. PubMed ID: 32210538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
    Wang F; Li L; Liu B; Chen Z; Li C
    Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C; Liu W; Hu Y; Li W; Di W
    Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.